This is further supported by the observation that disruption of the MDM2–p53 complex with a small molecule MDM2 inhibitor (Nutlin-3) resulted in the induction of P53 and increased cisplatin sensitivity in GCT cell lines that express WT TP53 [28,41,203]. The gene discussed is MDM2; the disease is granular cell tumor.